Outlook Therapeutics, Inc. income statement

In fiscal 2025, Outlook Therapeutics, Inc. reported revenue of $1.4m, down 82.6% on the year before, operating income of −$67.1m (a -4744.3% margin) and net income of −$62.4m, or −$1.79 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Outlook Therapeutics, Inc.: income statement, annual
Fiscal year	2015Sept 2015	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Sept 2019	2025Sept 2025
Revenue	5	3	4	3	8	1
Cost of revenue	—	—	—	—	—	1
Gross profit	—	—	—	—	—	0
Research and development	39	33	24	19	24	27
Selling, general and administrative	—	—	—	—	—	40
General and administrative	13	22	16	14	9	—
Operating income	−47	−51	−36	−30	−36	−67
Interest expense	2	2	6	4	3	—
Net interest income	—	—	—	—	—	−0
Income before tax	−49	−53	−38	−34	−38	−64
Income tax	−0	0	1	−4	−3	−2
Net income	−47	−53	−39	−30	−35	−62
Diluted EPS	−$108.60	−$3.67	−$1.80	−$24.40	−$39.60	−$1.79
Diluted shares (average)	—	—	1m	2m	—	35m
EBITDA	−45	−49	−33	−27	−33	−67

US$ millions unless shown otherwise. Fiscal quarters.

Outlook Therapeutics, Inc.: income statement, quarterly
Quarter	2018 Q3Jun 2018	2018 Q4Sept 2018	2019 Q1Dec 2018	2019 Q2Mar 2019	2019 Q3Jun 2019	2019 Q4Sept 2019	2025 Q3Jun 2025	2025 Q4Sept 2025
Revenue	1	1	1	1	1	6	2	−0
Cost of revenue	—	—	—	—	—	—	0	1
Gross profit	—	—	—	—	—	—	1	−1
Research and development	6	7	6	6	4	7	7	6
Selling, general and administrative	—	—	—	—	—	—	10	10
General and administrative	2	6	3	2	2	3	—	—
Operating income	−7	−12	−10	−8	−6	−13	−16	−17
Interest expense	1	1	1	1	1	0	—	—
Net interest income	—	—	—	—	—	—	−0	−0
Income before tax	−8	−13	−10	−10	−5	−13	−20	−15
Income tax	0	−0	—	—	−1	−3	0	−2
Net income	−8	−12	−10	−10	−4	−10	−20	−13
Diluted EPS	−$20.80	$0.20	−$10.00	−$9.80	−$4.00	−$4.80	−$0.55	−$0.19
EBITDA	−6	−12	−9	−7	−5	−12	−16	−17

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACRS vs OTLK COYA vs OTLK APLM vs OTLK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Outlook Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Outlook Therapeutics, Inc.